SARS-CoV-2突破性感染中的感染介导免疫应答及对下一代COVID-19疫苗研发的启示
本文综述了SARS-CoV-2突破性感染所引发的免疫应答,重点讨论影响血清中和抗体滴度幅度与广度的因素以及合适的加强疫苗接种策略。综述指出,突破性感染诱导的抗体应答与诊断时上呼吸道病毒载量及接种至感染间隔相关,可为下一代COVID-19疫苗研发提供关键信息。
要点
- 突破性感染者和第三剂加强接种者均可检出针对Omicron变异株的高滴度血清中和抗体。
- 突破性感染诱导的中和抗体滴度幅度与诊断时上呼吸道病毒载量相关,广度与接种至感染间隔相关。
- 突破性感染者接种至感染间隔长短不一,不同于加强接种者,可据此估算最佳加强接种间隔。
核心结论
- 突破性感染病例为评估疫苗诱导的针对SARS-CoV-2变异株的免疫及与临床状态相关的各种因素提供了仅靠研究接种者无法获得的有价值信息。
研究设计与样本
- 本文为综述,描述突破性感染所引发的免疫应答,讨论影响血清抗体滴度幅度与广度的因素及合适的加强疫苗接种策略。
主要发现
- 在SARS-CoV-2 Omicron波早期,突破性感染者及接受第三剂疫苗者(即加强接种者)均可检出针对Omicron变异株的高滴度血清中和抗体。
- Omicron抗原触发的免疫应答与疫苗株此前触发的免疫应答不同。
- 突破性感染诱导的中和抗体滴度幅度与诊断时上呼吸道病毒载量相关,广度与接种至感染间隔相关。
- 与加强接种者不同,突破性感染者接种至感染间隔长短不一。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Post-vaccination infections, termed breakthrough infections, occur after the virus infection overcomes the vaccine-induced immune barrier. During the early stages of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron wave, high serum-neutralizing antibody titers against the Omicron variant were detected in individuals with breakthrough infections as well as those who received a third vaccine dose (i.e., booster recipients). Additionally, these cases indicated that Omicron antigens triggered an immune response that differed from that triggered by the vaccine strain before analysis of the effectiveness of new vaccines updated for the Omicron variants. Moreover, the magnitude and breadth of neutralizing antibody titers induced by breakthrough infections are correlated with the upper respiratory viral load at diagnosis and the duration between vaccination and infection, respectively. Unlike booster vaccine recipients, patients with breakthrough infections have varying durations between vaccination and infection. Accordingly, optimal booster vaccination intervals may be estimated based on the cross-neutralizing antibody response induced over time. Examination of breakthrough infection cases has provided valuable insights that could not be yielded by only examining vaccinated individuals alone. These insights include estimates of vaccine-induced immunity against SARS-CoV-2 variants and the various factors related to the clinical status. This review describes the immune response elicited by breakthrough infections; specifically, it discusses factors that affect the magnitude and breadth of serum antibody titers as well as the appropriate booster vaccination strategy. This review provides key aspects that could contribute to developing next-generation COVID-19 vaccines through breakthrough infection cases.
引用
- Miyamoto S, Suzuki T. Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development. Vaccine. 2024. PMID: 38310015. doi:10.1016/j.vaccine.2024.01.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。